Member Info for Collette

Hmmmm dust this one off ..... reading the RNSs for the past week here ..... interesting ........ and up on a day like today. Does anybody follow this one?

Hyder year results to beat forecasts http://www.sharecast.com/cgi-bin/sharecast/story.cgi?story_id=3259287

Can't find any news but IMO volume here over past 2 days suggests somethings brewing.

Been watching this one for a while .... Huge volume / £2 + mill buy yesterday ... time to join you I think :)

2010 prediction round-up courtesy of Ptolemy http://pragcap.com/the-ultimate-guide-to-2010-investment-predictions-and-outlooks

http://investing.thisismoney.co.uk/cgi-bin/digitalcorporate/thisismoney/broker_rec.cgi

http://www.advfn.com/p.php?pid=nmona&cb=1262675151&article=40959406&symbol=L%5EMOG

DLTA appears to be making a bottom close to the 50% Fib retracement line and has a huge bullish divergence in RSI as well as the daily MACD...

5 year distribution agreement: http://www.advfn.com/p.php?pid=nmona&cb=1262589551&article=40942235&symbol=L%5EIDH

Is this one still on your watch list? "Thanks to henryatkin" it's on mine :)

source:sunday times Iain Dey ASTRA ZENECA Last year’s rally in the FTSE 100 index was fuelled by out-of-favour companies bouncing back from the brink of disaster. Now that the market has returned to higher levels, picking winners is a tougher game. Defensive companies are beginning to come back into favour with analysts and strategists. Astra Zeneca, the pharmaceuticals giant, is generating so much cash that analysts at UBS reckon it could raise its dividend. The shares are trading on less than eight times this year’s forecast earnings and already offer a prospective dividend yield of about 5%. Concerns about some of its big drug patents expiring have hampered the shares. However, Astra Zeneca sealed two deals in December that have brightened the outlook for its pipeline of new products. Its £220m takeover of the French antibiotics firm Novexel and a £720m deal to buy the rights for a new manic depression treatment were welcomed by the market. Tax breaks on research and development announced in the pre-budget report also bode well for the sector. Astra Zeneca should be a solid investment in an uncertain year but it could also come up with some nice surprises. Buy at £29.10

MoneyWeek.com - 21st December 2009 On 21st December, MoneyWeek.com published an article by Tom Bulford called "Three small-cap gambles for 2010" Nyota Minerals (NYO) Biofutures International (BIP) Minoan (MIN)

This has climbed steadily over the past 6 weeks on no news or volume .... Another potential star for 2010.

I half expect this to drop below 40p before the MMs will allow it to move north and with my stop at 28p I doubt the inevitable tree shake will close me out :) I have a 37p & 34p limit order sitting on the books so I can snap some more up if / when those pesky MMs decide to play their naughty games. lol

Like you I know this share .... April @ 42p ....... SLV was my first foray into SB I was wary, then and I still am. Start slowly, don't be greedy is my advice ...... My mental floor is 28p Malcolm Pryor is a good read :)

Yep 1p :)

I just see it as an opportunity to load up my spread bet at these levels £100s of £ a point so when it does move I will be more than delighted and loading up some more :)

Lovely chart here too :))

Council Pop is all I picked up here .... it needs a good kick.

http://www.alterian.com/news__events/press_releases/2009/20091218_forrester_cm_wave.aspx and http://www.citywire.co.uk/personal/-/news/markets-companies-and-funds/content.aspx?ID=374181&Page=1 "Panmure Gordon...has a buy for Alterian, raising target to 241p from 239p"